Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
31,889
archived clinical trials in
Blood Cancer

Targeting Inattention in Childhood Cancer Survivors (TRICCS)
TRICCS: Targeting Inattention in Childhood Cancer Survivors
Status: Enrolling
Updated:  8/13/2008
Duke Univ Med Ctr
mi
from
Durham, NC
Targeting Inattention in Childhood Cancer Survivors (TRICCS)
TRICCS: Targeting Inattention in Childhood Cancer Survivors
Status: Enrolling
Updated: 8/13/2008
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Study of Cordycepin Plus Pentostatin in Patients With Refractory TdT-Positive Leukemia
A Phase I/II Study of Cordycepin Plus Pentostatin in Patients With Refractory TdT-Positive Leukemia
Status: Enrolling
Updated:  1/8/2009
Brigham and Women's Hosp
mi
from
Boston, MA
Study of Cordycepin Plus Pentostatin in Patients With Refractory TdT-Positive Leukemia
A Phase I/II Study of Cordycepin Plus Pentostatin in Patients With Refractory TdT-Positive Leukemia
Status: Enrolling
Updated: 1/8/2009
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
Study of Cordycepin Plus Pentostatin in Patients With Refractory TdT-Positive Leukemia
A Phase I/II Study of Cordycepin Plus Pentostatin in Patients With Refractory TdT-Positive Leukemia
Status: Enrolling
Updated:  1/8/2009
Dana-Farber Cancer Institute
mi
from
Boston, MA
Study of Cordycepin Plus Pentostatin in Patients With Refractory TdT-Positive Leukemia
A Phase I/II Study of Cordycepin Plus Pentostatin in Patients With Refractory TdT-Positive Leukemia
Status: Enrolling
Updated: 1/8/2009
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Study of Cordycepin Plus Pentostatin in Patients With Refractory TdT-Positive Leukemia
A Phase I/II Study of Cordycepin Plus Pentostatin in Patients With Refractory TdT-Positive Leukemia
Status: Enrolling
Updated:  1/8/2009
Cancer Therapy Reasearch Center at UTHSCA
mi
from
San Antonio, TX
Study of Cordycepin Plus Pentostatin in Patients With Refractory TdT-Positive Leukemia
A Phase I/II Study of Cordycepin Plus Pentostatin in Patients With Refractory TdT-Positive Leukemia
Status: Enrolling
Updated: 1/8/2009
Cancer Therapy Reasearch Center at UTHSCA
mi
from
San Antonio, TX
Click here to add this to my saved trials
Study of Fluphenazine in Relapsed or Relapsed-and-Refractory Multiple Myeloma
Phase 1b Single Arm, Open Label, Multi-Center Study of Fluphenazine HCl Monotherapy in Relapsed or Relapsed-and-Refractory Multiple Myeloma
Status: Enrolling
Updated:  1/12/2009
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Study of Fluphenazine in Relapsed or Relapsed-and-Refractory Multiple Myeloma
Phase 1b Single Arm, Open Label, Multi-Center Study of Fluphenazine HCl Monotherapy in Relapsed or Relapsed-and-Refractory Multiple Myeloma
Status: Enrolling
Updated: 1/12/2009
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Study of Fluphenazine in Relapsed or Relapsed-and-Refractory Multiple Myeloma
Phase 1b Single Arm, Open Label, Multi-Center Study of Fluphenazine HCl Monotherapy in Relapsed or Relapsed-and-Refractory Multiple Myeloma
Status: Enrolling
Updated:  1/12/2009
University of Pittsburgh Cancer Institute / Hillman Cancer Center
mi
from
Pittsburgh, PA
Study of Fluphenazine in Relapsed or Relapsed-and-Refractory Multiple Myeloma
Phase 1b Single Arm, Open Label, Multi-Center Study of Fluphenazine HCl Monotherapy in Relapsed or Relapsed-and-Refractory Multiple Myeloma
Status: Enrolling
Updated: 1/12/2009
University of Pittsburgh Cancer Institute / Hillman Cancer Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Study of Fluphenazine in Relapsed or Relapsed-and-Refractory Multiple Myeloma
Phase 1b Single Arm, Open Label, Multi-Center Study of Fluphenazine HCl Monotherapy in Relapsed or Relapsed-and-Refractory Multiple Myeloma
Status: Enrolling
Updated:  1/12/2009
Cancer Therapy and Research Center at the UT Health Sciences Center at San Antonio
mi
from
San Antonio, TX
Study of Fluphenazine in Relapsed or Relapsed-and-Refractory Multiple Myeloma
Phase 1b Single Arm, Open Label, Multi-Center Study of Fluphenazine HCl Monotherapy in Relapsed or Relapsed-and-Refractory Multiple Myeloma
Status: Enrolling
Updated: 1/12/2009
Cancer Therapy and Research Center at the UT Health Sciences Center at San Antonio
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Trial of Extracorporeal Photopheresis, Pentostatin, and Total Body Irradiation in Patients Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation for the Treatment of Malignancies
A Randomized Trial of Extracorporeal Photopheresis, Pentostatin, and Total Body Irradiation Versus Pentostatin and Total Body Irradiation in Patients Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation for the Treatment of Malignancies
Status: Enrolling
Updated:  4/28/2009
Methodist Hospital - Texas Transplant Institute
mi
from
San Antonio, TX
A Trial of Extracorporeal Photopheresis, Pentostatin, and Total Body Irradiation in Patients Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation for the Treatment of Malignancies
A Randomized Trial of Extracorporeal Photopheresis, Pentostatin, and Total Body Irradiation Versus Pentostatin and Total Body Irradiation in Patients Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation for the Treatment of Malignancies
Status: Enrolling
Updated: 4/28/2009
Methodist Hospital - Texas Transplant Institute
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Trial of Extracorporeal Photopheresis, Pentostatin, and Total Body Irradiation in Patients Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation for the Treatment of Malignancies
A Randomized Trial of Extracorporeal Photopheresis, Pentostatin, and Total Body Irradiation Versus Pentostatin and Total Body Irradiation in Patients Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation for the Treatment of Malignancies
Status: Enrolling
Updated:  4/28/2009
Tufts - New England Medical Center
mi
from
Boston, MA
A Trial of Extracorporeal Photopheresis, Pentostatin, and Total Body Irradiation in Patients Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation for the Treatment of Malignancies
A Randomized Trial of Extracorporeal Photopheresis, Pentostatin, and Total Body Irradiation Versus Pentostatin and Total Body Irradiation in Patients Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation for the Treatment of Malignancies
Status: Enrolling
Updated: 4/28/2009
Tufts - New England Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
A Trial of Extracorporeal Photopheresis, Pentostatin, and Total Body Irradiation in Patients Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation for the Treatment of Malignancies
A Randomized Trial of Extracorporeal Photopheresis, Pentostatin, and Total Body Irradiation Versus Pentostatin and Total Body Irradiation in Patients Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation for the Treatment of Malignancies
Status: Enrolling
Updated:  4/28/2009
Yale Comprehensive Cancer Center at Yale University School of Medicine
mi
from
New Haven, CT
A Trial of Extracorporeal Photopheresis, Pentostatin, and Total Body Irradiation in Patients Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation for the Treatment of Malignancies
A Randomized Trial of Extracorporeal Photopheresis, Pentostatin, and Total Body Irradiation Versus Pentostatin and Total Body Irradiation in Patients Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation for the Treatment of Malignancies
Status: Enrolling
Updated: 4/28/2009
Yale Comprehensive Cancer Center at Yale University School of Medicine
mi
from
New Haven, CT
Click here to add this to my saved trials
Effects of Antithymocyte Globulin in Adults With Myelodysplastic Syndrome
Mechanism and Response of Thymoglobulin in Patients With Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  6/1/2009
UCLA Oncology Center
mi
from
Los Angeles, CA
Effects of Antithymocyte Globulin in Adults With Myelodysplastic Syndrome
Mechanism and Response of Thymoglobulin in Patients With Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 6/1/2009
UCLA Oncology Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Effects of Antithymocyte Globulin in Adults With Myelodysplastic Syndrome
Mechanism and Response of Thymoglobulin in Patients With Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  6/1/2009
H. Lee Moffitt Cancer Center
mi
from
Tampa, FL
Effects of Antithymocyte Globulin in Adults With Myelodysplastic Syndrome
Mechanism and Response of Thymoglobulin in Patients With Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 6/1/2009
H. Lee Moffitt Cancer Center
mi
from
Tampa, FL
Click here to add this to my saved trials
Effects of Antithymocyte Globulin in Adults With Myelodysplastic Syndrome
Mechanism and Response of Thymoglobulin in Patients With Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  6/1/2009
Cleveland Clinic Foundation - Case Western University
mi
from
Cleveland, OH
Effects of Antithymocyte Globulin in Adults With Myelodysplastic Syndrome
Mechanism and Response of Thymoglobulin in Patients With Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 6/1/2009
Cleveland Clinic Foundation - Case Western University
mi
from
Cleveland, OH
Click here to add this to my saved trials
Effects of Antithymocyte Globulin in Adults With Myelodysplastic Syndrome
Mechanism and Response of Thymoglobulin in Patients With Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  6/1/2009
Penn State University
mi
from
Hershey, PA
Effects of Antithymocyte Globulin in Adults With Myelodysplastic Syndrome
Mechanism and Response of Thymoglobulin in Patients With Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 6/1/2009
Penn State University
mi
from
Hershey, PA
Click here to add this to my saved trials
A Study Using Two Oral Chemotherapy Agents for Chronic Lymphocytic Leukemia
A Phase I/II Study of Combination Dasatinib and Lenalidomide in Purine Analogue-Failed Chronic Lymphocytic Leukemia
Status: Enrolling
Updated:  10/13/2009
Scripps Cancer Center
mi
from
La Jolla, CA
A Study Using Two Oral Chemotherapy Agents for Chronic Lymphocytic Leukemia
A Phase I/II Study of Combination Dasatinib and Lenalidomide in Purine Analogue-Failed Chronic Lymphocytic Leukemia
Status: Enrolling
Updated: 10/13/2009
Scripps Cancer Center
mi
from
La Jolla, CA
Click here to add this to my saved trials
Intentional Rejection of the Donor Graft Using Recipient Leukocyte Infusion(s) Following Nonmyeloablative Allogeneic Stem Cell Transplantation
Intentional Rejection of the Donor Graft Using Recipient Leukocyte Infusion(s) Following Nonmyeloablative Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  5/3/2010
Massachusetts General Hospital
mi
from
Boston, MA
Intentional Rejection of the Donor Graft Using Recipient Leukocyte Infusion(s) Following Nonmyeloablative Allogeneic Stem Cell Transplantation
Intentional Rejection of the Donor Graft Using Recipient Leukocyte Infusion(s) Following Nonmyeloablative Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 5/3/2010
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Cytokine Induced Killer Cells as Post-Transplant Immunotherapy Following Allogeneic Hematopoietic Cell Transplantation
Cytokine Induced Killer Cells as Post-Transplant Immunotherapy Following Allogeneic Hematopoietic Cell Transplantation
Status: Enrolling
Updated:  9/8/2010
Stanford University School of Medicine
mi
from
Stanford, CA
Cytokine Induced Killer Cells as Post-Transplant Immunotherapy Following Allogeneic Hematopoietic Cell Transplantation
Cytokine Induced Killer Cells as Post-Transplant Immunotherapy Following Allogeneic Hematopoietic Cell Transplantation
Status: Enrolling
Updated: 9/8/2010
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)
A Two-Arm, Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment in Patients With B-cell Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated:  9/8/2010
The University of California, San Diego
mi
from
La Jolla, CA
Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)
A Two-Arm, Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment in Patients With B-cell Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 9/8/2010
The University of California, San Diego
mi
from
La Jolla, CA
Click here to add this to my saved trials
Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)
A Two-Arm, Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment in Patients With B-cell Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated:  9/8/2010
Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute
mi
from
Boston, MA
Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)
A Two-Arm, Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment in Patients With B-cell Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 9/8/2010
Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)
A Two-Arm, Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment in Patients With B-cell Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated:  9/8/2010
Long Island Jewish Medical Center
mi
from
New Hyde Park, NY
Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)
A Two-Arm, Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment in Patients With B-cell Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 9/8/2010
Long Island Jewish Medical Center
mi
from
New Hyde Park, NY
Click here to add this to my saved trials
Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)
A Two-Arm, Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment in Patients With B-cell Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated:  9/8/2010
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University
mi
from
Columbus, OH
Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)
A Two-Arm, Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment in Patients With B-cell Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 9/8/2010
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)
A Two-Arm, Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment in Patients With B-cell Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated:  9/8/2010
M. D. Anderson Cancer Center at University of Texas
mi
from
Houston, TX
Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)
A Two-Arm, Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment in Patients With B-cell Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 9/8/2010
M. D. Anderson Cancer Center at University of Texas
mi
from
Houston, TX
Click here to add this to my saved trials
Cancer: Thriving and Surviving Online Workshop and Study for Cancer Survivors
Cancer Survivors Online Self-Management Workshop
Status: Enrolling
Updated:  9/8/2010
Stanford University School of Medicine
mi
from
Stanford, CA
Cancer: Thriving and Surviving Online Workshop and Study for Cancer Survivors
Cancer Survivors Online Self-Management Workshop
Status: Enrolling
Updated: 9/8/2010
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
IGF-1 Inhibitor Pasireotide Lar in Combination With the m-TOR Inhibitor Everolimus
Phase II Study of the IGF-1 Inhibitor Pasireotide Lar in Combination With the m-TOR Inhibitor Everolimus in Patients With Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  11/3/2010
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
IGF-1 Inhibitor Pasireotide Lar in Combination With the m-TOR Inhibitor Everolimus
Phase II Study of the IGF-1 Inhibitor Pasireotide Lar in Combination With the m-TOR Inhibitor Everolimus in Patients With Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 11/3/2010
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
Study in Patients With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis
A Phase 2 Study to Evaluate the Efficacy and Safety of AB0024 in Adult Patients With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  11/17/2010
Stanford University Cancer Institute
mi
from
Stanford, CA
Study in Patients With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis
A Phase 2 Study to Evaluate the Efficacy and Safety of AB0024 in Adult Patients With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 11/17/2010
Stanford University Cancer Institute
mi
from
Stanford, CA
Click here to add this to my saved trials
Study in Patients With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis
A Phase 2 Study to Evaluate the Efficacy and Safety of AB0024 in Adult Patients With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated:  11/17/2010
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Study in Patients With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis
A Phase 2 Study to Evaluate the Efficacy and Safety of AB0024 in Adult Patients With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis
Status: Enrolling
Updated: 11/17/2010
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Study Elesclomol Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia
A Phase 1 Dose-Escalation Study of Elesclomol Sodium Administered Intravenously to Subjects With Relapsed or Refractory Acute Myeloid Leukemia
Status: Enrolling
Updated:  1/31/2011
Memorial Sloan-Kettering Cancer Center
mi
from
New York, NY
Study Elesclomol Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia
A Phase 1 Dose-Escalation Study of Elesclomol Sodium Administered Intravenously to Subjects With Relapsed or Refractory Acute Myeloid Leukemia
Status: Enrolling
Updated: 1/31/2011
Memorial Sloan-Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
IV Plerixafor With Mitoxantrone Etoposide and Cytarabine for Acute Myeloid Leukemia (AML)
A Phase I Study of Intravenous Plerixafor in Combination With Mitoxantrone Etoposide and Cytarabine for Relapsed or Refractory Acute Myeloid Leukemia
Status: Enrolling
Updated:  2/25/2011
Washington University School of Medicine
mi
from
Saint Louis, MO
IV Plerixafor With Mitoxantrone Etoposide and Cytarabine for Acute Myeloid Leukemia (AML)
A Phase I Study of Intravenous Plerixafor in Combination With Mitoxantrone Etoposide and Cytarabine for Relapsed or Refractory Acute Myeloid Leukemia
Status: Enrolling
Updated: 2/25/2011
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Reduced Intensity Transplant Using Extracorporeal Photopheresis
Reduced Intensity Stem Cell Transplant in Children and Young Adults Utilizing Photopheresis, Fludarabine, and Busulfan
Status: Enrolling
Updated:  3/10/2011
Children's Memorial Hospital
mi
from
Chicago, IL
Reduced Intensity Transplant Using Extracorporeal Photopheresis
Reduced Intensity Stem Cell Transplant in Children and Young Adults Utilizing Photopheresis, Fludarabine, and Busulfan
Status: Enrolling
Updated: 3/10/2011
Children's Memorial Hospital
mi
from
Chicago, IL
Click here to add this to my saved trials
Pilot Lenalidomide in Adult Diamond-Blackfan Anemia Patients w/ RBC Transfusion-Dependent Anemia
A Pilot Study of Lenalidomide in Adult Diamond-Blackfan Anemia Patients With Red Blood Cell Transfusion-Dependent Anemia
Status: Enrolling
Updated:  3/21/2011
Stanford University School of Medicine
mi
from
Stanford, CA
Pilot Lenalidomide in Adult Diamond-Blackfan Anemia Patients w/ RBC Transfusion-Dependent Anemia
A Pilot Study of Lenalidomide in Adult Diamond-Blackfan Anemia Patients With Red Blood Cell Transfusion-Dependent Anemia
Status: Enrolling
Updated: 3/21/2011
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
Dose-escalation Study of Oral CX-4945
A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of CX-4945 Administered Orally to Patients With Advanced Solid Tumors, Castleman's Disease or Multiple Myeloma
Status: Enrolling
Updated:  6/13/2011
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Dose-escalation Study of Oral CX-4945
A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of CX-4945 Administered Orally to Patients With Advanced Solid Tumors, Castleman's Disease or Multiple Myeloma
Status: Enrolling
Updated: 6/13/2011
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Dose-escalation Study of Oral CX-4945
A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of CX-4945 Administered Orally to Patients With Advanced Solid Tumors, Castleman's Disease or Multiple Myeloma
Status: Enrolling
Updated:  6/13/2011
Front Range Cancer Specialists
mi
from
Fort Collins, CO
Dose-escalation Study of Oral CX-4945
A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of CX-4945 Administered Orally to Patients With Advanced Solid Tumors, Castleman's Disease or Multiple Myeloma
Status: Enrolling
Updated: 6/13/2011
Front Range Cancer Specialists
mi
from
Fort Collins, CO
Click here to add this to my saved trials
Dose-escalation Study of Oral CX-4945
A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of CX-4945 Administered Orally to Patients With Advanced Solid Tumors, Castleman's Disease or Multiple Myeloma
Status: Enrolling
Updated:  6/13/2011
Front Range Cancer Specialists
mi
from
Loveland, CO
Dose-escalation Study of Oral CX-4945
A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of CX-4945 Administered Orally to Patients With Advanced Solid Tumors, Castleman's Disease or Multiple Myeloma
Status: Enrolling
Updated: 6/13/2011
Front Range Cancer Specialists
mi
from
Loveland, CO
Click here to add this to my saved trials
Dose-escalation Study of Oral CX-4945
A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of CX-4945 Administered Orally to Patients With Advanced Solid Tumors, Castleman's Disease or Multiple Myeloma
Status: Enrolling
Updated:  6/13/2011
U T M D Anderson Cancer Center
mi
from
Houston, TX
Dose-escalation Study of Oral CX-4945
A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of CX-4945 Administered Orally to Patients With Advanced Solid Tumors, Castleman's Disease or Multiple Myeloma
Status: Enrolling
Updated: 6/13/2011
U T M D Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma
A Phase 1, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of CX-4945 Administered Orally to Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  6/13/2011
Clinical Research Facility
mi
from
Kettering, OH
Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma
A Phase 1, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of CX-4945 Administered Orally to Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 6/13/2011
Clinical Research Facility
mi
from
Kettering, OH
Click here to add this to my saved trials
Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma
A Phase 1, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of CX-4945 Administered Orally to Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  6/13/2011
Oregon Health and Science University
mi
from
Portland, OR
Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma
A Phase 1, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of CX-4945 Administered Orally to Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 6/13/2011
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma
A Phase 1, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of CX-4945 Administered Orally to Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  6/13/2011
Clinical Research Facility
mi
from
Springfield, OR
Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma
A Phase 1, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of CX-4945 Administered Orally to Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 6/13/2011
Clinical Research Facility
mi
from
Springfield, OR
Click here to add this to my saved trials
Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma
A Phase 1, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of CX-4945 Administered Orally to Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  6/13/2011
Clinical Research Facility
mi
from
Greenville, SC
Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma
A Phase 1, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of CX-4945 Administered Orally to Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 6/13/2011
Clinical Research Facility
mi
from
Greenville, SC
Click here to add this to my saved trials
Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma
A Phase 1, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of CX-4945 Administered Orally to Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  6/13/2011
Clinical Research Facility
mi
from
Norfolk, VA
Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma
A Phase 1, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of CX-4945 Administered Orally to Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 6/13/2011
Clinical Research Facility
mi
from
Norfolk, VA
Click here to add this to my saved trials
Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma
A Phase 1, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of CX-4945 Administered Orally to Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  6/13/2011
Clinical Research Facility
mi
from
Yakima, WA
Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma
A Phase 1, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of CX-4945 Administered Orally to Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 6/13/2011
Clinical Research Facility
mi
from
Yakima, WA
Click here to add this to my saved trials
A Phase II Study Of Imtox-25 In Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma
Phase II Study of Therapy With IMTOX-25 in Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma
Status: Enrolling
Updated:  6/22/2011
Albert Einstein Cancer Center
mi
from
Bronx, NY
A Phase II Study Of Imtox-25 In Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma
Phase II Study of Therapy With IMTOX-25 in Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma
Status: Enrolling
Updated: 6/22/2011
Albert Einstein Cancer Center
mi
from
Bronx, NY
Click here to add this to my saved trials
A Phase II Study Of Imtox-25 In Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma
Phase II Study of Therapy With IMTOX-25 in Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma
Status: Enrolling
Updated:  6/22/2011
Albert Einstein Cancer Center
mi
from
Bronx, NY
A Phase II Study Of Imtox-25 In Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma
Phase II Study of Therapy With IMTOX-25 in Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma
Status: Enrolling
Updated: 6/22/2011
Albert Einstein Cancer Center
mi
from
Bronx, NY
Click here to add this to my saved trials
A Phase II Study Of Imtox-25 In Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma
Phase II Study of Therapy With IMTOX-25 in Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma
Status: Enrolling
Updated:  6/22/2011
Albert Einstein Cancer Center at Albert Einstein College of Medicine
mi
from
Bronx, NY
A Phase II Study Of Imtox-25 In Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma
Phase II Study of Therapy With IMTOX-25 in Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma
Status: Enrolling
Updated: 6/22/2011
Albert Einstein Cancer Center at Albert Einstein College of Medicine
mi
from
Bronx, NY
Click here to add this to my saved trials
A Phase II Study Of Imtox-25 In Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma
Phase II Study of Therapy With IMTOX-25 in Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma
Status: Enrolling
Updated:  6/22/2011
Albert Einstein Cancer Center at Albert Einstein College of Medicine
mi
from
Bronx, NY
A Phase II Study Of Imtox-25 In Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma
Phase II Study of Therapy With IMTOX-25 in Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma
Status: Enrolling
Updated: 6/22/2011
Albert Einstein Cancer Center at Albert Einstein College of Medicine
mi
from
Bronx, NY
Click here to add this to my saved trials
A Phase II Study Of Imtox-25 In Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma
Phase II Study of Therapy With IMTOX-25 in Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma
Status: Enrolling
Updated:  6/22/2011
Albert Einstein Cancer Center at Albert Einstein College of Medicine
mi
from
Bronx, NY
A Phase II Study Of Imtox-25 In Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma
Phase II Study of Therapy With IMTOX-25 in Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma
Status: Enrolling
Updated: 6/22/2011
Albert Einstein Cancer Center at Albert Einstein College of Medicine
mi
from
Bronx, NY
Click here to add this to my saved trials
A Phase II Study Of Imtox-25 In Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma
Phase II Study of Therapy With IMTOX-25 in Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma
Status: Enrolling
Updated:  6/22/2011
Albert Einstein Clinical Cancer Center
mi
from
Bronx, NY
A Phase II Study Of Imtox-25 In Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma
Phase II Study of Therapy With IMTOX-25 in Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma
Status: Enrolling
Updated: 6/22/2011
Albert Einstein Clinical Cancer Center
mi
from
Bronx, NY
Click here to add this to my saved trials
A Phase II Study Of Imtox-25 In Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma
Phase II Study of Therapy With IMTOX-25 in Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma
Status: Enrolling
Updated:  6/22/2011
Albert Einstein Comprehensive Cancer Center
mi
from
Bronx, NY
A Phase II Study Of Imtox-25 In Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma
Phase II Study of Therapy With IMTOX-25 in Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma
Status: Enrolling
Updated: 6/22/2011
Albert Einstein Comprehensive Cancer Center
mi
from
Bronx, NY
Click here to add this to my saved trials
A Phase II Study Of Imtox-25 In Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma
Phase II Study of Therapy With IMTOX-25 in Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma
Status: Enrolling
Updated:  6/22/2011
Albert Einstein Comprehensive Cancer Center
mi
from
Bronx, NY
A Phase II Study Of Imtox-25 In Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma
Phase II Study of Therapy With IMTOX-25 in Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma
Status: Enrolling
Updated: 6/22/2011
Albert Einstein Comprehensive Cancer Center
mi
from
Bronx, NY
Click here to add this to my saved trials
A Phase II Study Of Imtox-25 In Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma
Phase II Study of Therapy With IMTOX-25 in Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma
Status: Enrolling
Updated:  6/22/2011
Montefiore Medical Center
mi
from
Bronx, NY
A Phase II Study Of Imtox-25 In Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma
Phase II Study of Therapy With IMTOX-25 in Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma
Status: Enrolling
Updated: 6/22/2011
Montefiore Medical Center
mi
from
Bronx, NY
Click here to add this to my saved trials
A Phase II Study Of Imtox-25 In Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma
Phase II Study of Therapy With IMTOX-25 in Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma
Status: Enrolling
Updated:  6/22/2011
Montefiore Medical Center
mi
from
Bronx, NY
A Phase II Study Of Imtox-25 In Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma
Phase II Study of Therapy With IMTOX-25 in Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma
Status: Enrolling
Updated: 6/22/2011
Montefiore Medical Center
mi
from
Bronx, NY
Click here to add this to my saved trials